{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:20:32Z","timestamp":1791238832054,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"DOI":"10.7759\/cureus.42791","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T11:54:10Z","timestamp":1690890850000},"source":"Crossref","is-referenced-by-count":25,"title":["Paradoxical Tumor Necrosis Factor-Alpha (TNF-\u03b1) Inhibitor-Induced Psoriasis: A Systematic Review of Pathogenesis, Clinical Presentation, and Treatment"],"prefix":"10.7759","author":[{"given":"Aditi","family":"Chokshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Demory Beckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Laloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc M","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang DI","year":"2021","unstructured":"Jang DI, Lee AH, Shin HY, et al.. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021, 22:10.3390\/ijms22052719","journal-title":"Int J Mol Sci"},{"key":"ref2","article-title":"TNF in the inflammatory response","volume":"74","author":"M\u00e4nnel DN","year":"2000","unstructured":"M\u00e4nnel DN, Echtenacher B. TNF in the inflammatory response. Chem Immunol. 2000, 74:141-61.","journal-title":"Chem Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(92)90116-O","article-title":"Two TNF receptors","volume":"13","author":"Tartaglia LA","year":"1992","unstructured":"Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today. 1992, 13:151-3. 10.1016\/0167-5699(92)90116-O","journal-title":"Immunol Today"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou X","year":"2022","unstructured":"Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022, 13:81. 10.1038\/s41419-022-04523-3","journal-title":"Cell Death Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions","volume":"143","author":"de Gannes GC","year":"2007","unstructured":"de Gannes GC, Ghoreishi M, Pope J, et al.. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007, 143:223-31. 10.1001\/archderm.143.2.223","journal-title":"Arch Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors - state of knowledge","volume":"10","author":"Lis K","year":"2014","unstructured":"Lis K, Kuzawi\u0144ska O, Ba\u0142kowiec-Iskra E. Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci. 2014, 10:1175-85. 10.5114\/aoms.2014.47827","journal-title":"Arch Med Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon A","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019, 20:1475. 10.3390\/ijms20061475","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031482","article-title":"Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha","volume":"199","author":"Boyman O","year":"2004","unstructured":"Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med. 2004, 199:731-6. 10.1084\/jem.20031482","journal-title":"J Exp Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle FO","year":"2005","unstructured":"Nestle FO, Conrad C, Tun-Kyi A, et al.. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005, 202:135-43. 10.1084\/jem.20050500","journal-title":"J Exp Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23923.x","article-title":"Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha","volume":"125","author":"Nestle FO","year":"2005","unstructured":"Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol. 2005, 125:xiv-xv. 10.1111\/j.0022-202X.2005.23923.x","journal-title":"J Invest Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14139","article-title":"Pathogenesis of psoriasis and development of treatment","volume":"45","author":"Ogawa E","year":"2018","unstructured":"Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018, 45:264-72. 10.1111\/1346-8138.14139","journal-title":"J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217873","article-title":"Paradoxical psoriasis induced by anti-TNF\u03b1 treatment: evaluation of disease-specific clinical and genetic markers","volume":"21","author":"Bucalo A","year":"2020","unstructured":"Bucalo A, Rega F, Zangrilli A, et al.. Paradoxical psoriasis induced by anti-TNF\u03b1 treatment: evaluation of disease-specific clinical and genetic markers. Int J Mol Sci. 2020, 21:7873. 10.3390\/ijms21217873","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer AN","year":"2008","unstructured":"Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008, 59:996-1001. 10.1002\/art.23835","journal-title":"Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack C","year":"2014","unstructured":"Tillack C, Ehmann LM, Friedrich M, et al.. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment. Gut. 2014, 63:567-77. 10.1136\/gutjnl-2012-302853","journal-title":"Gut"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad C","year":"2018","unstructured":"Conrad C, Di Domizio J, Mylonas A, et al.. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018, 9:25. 10.1038\/s41467-017-02466-4","journal-title":"Nat Commun"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: Classical vs. paradoxical. The yin-yang of TNF and type I interferon","volume":"9","author":"Mylonas A","year":"2018","unstructured":"Mylonas A, Conrad C. Psoriasis: Classical vs. paradoxical. The yin-yang of TNF and type I interferon. Front Immunol. 2018, 9:2746. 10.3389\/fimmu.2018.02746","journal-title":"Front Immunol"},{"key":"ref17","article-title":"Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series","volume":"30","author":"Jarrett SJ","year":"2003","unstructured":"Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003, 30:2287-91.","journal-title":"J Rheumatol"},{"key":"ref18","article-title":"Pustular psoriasis induced by infliximab","volume":"3","author":"Thurber M","year":"2004","unstructured":"Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol. 2004, 3:439-40.","journal-title":"J Drugs Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C477","article-title":"Psoriasiform eruption induced by infliximab","volume":"38","author":"Verea MM","year":"2004","unstructured":"Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004, 38:54-7. 10.1345\/aph.1C477","journal-title":"Ann Pharmacother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/art.20155","article-title":"Skin reaction to adalimumab","volume":"50","author":"Beuthien W","year":"2004","unstructured":"Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum. 2004, 50:1690-2. 10.1002\/art.20155","journal-title":"Arthritis Rheum"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06107.x","article-title":"Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases","volume":"151","author":"Dereure O","year":"2004","unstructured":"Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol. 2004, 151:506-7. 10.1111\/j.1365-2133.2004.06107.x","journal-title":"Br J Dermatol"},{"key":"ref22","article-title":"Unexpected new onset or ecacerbation of psoriasis in treatment of active anlylosing spondylitis with TNF-alpha blocking agents: four case reports","volume":"63","author":"Haibel H","year":"2004","unstructured":"Haibel H. Unexpected new onset or ecacerbation of psoriasis in treatment of active anlylosing spondylitis with TNF-alpha blocking agents: four case reports. Ann Rheum Dis. 2004, 63:405.","journal-title":"Ann Rheum Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction","volume":"52","author":"Sfikakis PP","year":"2005","unstructured":"Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005, 52:2513-8. 10.1002\/art.21233","journal-title":"Arthritis Rheum"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/art.20954","article-title":"Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al","volume":"52","author":"Grinblat B","year":"2005","unstructured":"Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum. 2005, 52:1333-4; author reply 1334. 10.1002\/art.20954","journal-title":"Arthritis Rheum"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06977.x","article-title":"Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct?","volume":"153","author":"Micha\u00eblsson G","year":"2005","unstructured":"Micha\u00eblsson G, Kajermo U, Micha\u00eblsson A, Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct?. Br J Dermatol. 2005, 153:1243-4. 10.1111\/j.1365-2133.2005.06977.x","journal-title":"Br J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-004-0567-5","article-title":"Pustular skin lesions in patients treated with infliximab: report of two cases","volume":"25","author":"Starmans-Kool MJ","year":"2005","unstructured":"Starmans-Kool MJ, Peeters HR, Houben HH. Pustular skin lesions in patients treated with infliximab: report of two cases. Rheumatol Int. 2005, 25:550-2. 10.1007\/s00296-004-0567-5","journal-title":"Rheumatol Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01882.x","article-title":"Onset of flexural psoriasis during infliximab treatment for Crohn's disease","volume":"30","author":"Peramiquel L","year":"2005","unstructured":"Peramiquel L, Puig L, Dalmau J, Ricart E, Roe E, Alomar A. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol. 2005, 30:713-4. 10.1111\/j.1365-2230.2005.01882.x","journal-title":"Clin Exp Dermatol"},{"key":"ref28","article-title":"Pustulose palmaire et plantaire chez une patiente traitee par adalimumab [Article in French]","volume":"72","author":"Zarinitsky C: Pustulose palmaire et plantaire chez une patiente traitee par adalimumab","year":"2005","unstructured":"Zarinitsky C. Pustulose palmaire et plantaire chez une patiente traitee par adalimumab: Pustulose palmaire et plantaire chez une patiente traitee par adalimumab [Article in French]. RevRhum. 2005, 72:1195.","journal-title":"RevRhum"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists","volume":"65","author":"Kary S","year":"2006","unstructured":"Kary S, Worm M, Audring H, et al.. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis. 2006, 65:405-7. 10.1136\/ard.2005.037424","journal-title":"Ann Rheum Dis"},{"key":"ref30","article-title":"Infliximab associated new-onset psoriasis","volume":"5","author":"Adams DR","year":"2006","unstructured":"Adams DR, Buckel T, Sceppa JA. Infliximab associated new-onset psoriasis. J Drugs Dermatol. 2006, 5:178-9.","journal-title":"J Drugs Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.040576","article-title":"Development of new-onset psoriasis while on anti-TNFalpha treatment","volume":"65","author":"Matthews C","year":"2006","unstructured":"Matthews C, Rogers S, FitzGerald O. Development of new-onset psoriasis while on anti-TNFalpha treatment. Ann Rheum Dis. 2006, 65:1529-30. 10.1136\/ard.2005.040576","journal-title":"Ann Rheum Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2006.02315.x","article-title":"Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers","volume":"32","author":"Goiriz R","year":"2007","unstructured":"Goiriz R, Daud\u00e9n E, P\u00e9rez-Gala S, Guhl G, Garc\u00eda-D\u00edez A. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol. 2007, 32:176-9. 10.1111\/j.1365-2230.2006.02315.x","journal-title":"Clin Exp Dermatol"},{"key":"ref33","article-title":"Anti-tumor necrosis factor-alpha-induced psoriasis","volume":"33","author":"Sari I","year":"2006","unstructured":"Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. Anti-tumor necrosis factor-alpha-induced psoriasis. Journal of rheumatology. 2006, 33:1411-4.","journal-title":"Journal of rheumatology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1159\/000095033","article-title":"Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview","volume":"213","author":"Pirard D","year":"2006","unstructured":"Pirard D, Arco D, Debrouckere V, Heenen M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology. 2006, 213:182-6. 10.1159\/000095033","journal-title":"Dermatology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-006-0144-1","article-title":"Psoriasis onset during infliximab treatment: description of two cases","volume":"26","author":"Volpe A","year":"2006","unstructured":"Volpe A, Caramaschi P, Carletto A, Pieropan S, Bambara LM, Biasi D. Psoriasis onset during infliximab treatment: description of two cases. Rheumatol Int. 2006, 26:1158-60. 10.1007\/s00296-006-0144-1","journal-title":"Rheumatol Int"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1016\/S0025-7753(06)72243-6","article-title":"Psoriasis inducida por infliximab: unhecho parad\u00f3jico [Article in Spanish]","volume":"127","author":"GONZ\u00c1LEZ-L\u00d3PEZ M","year":"2006","unstructured":"GONZ\u00c1LEZ-L\u00d3PEZ M, Blanco-Alonso R, Y\u00e1nez-D\u00edaz S. Psoriasis inducida por infliximab: unhecho parad\u00f3jico [Article in Spanish]. Med Clin (Barc. 2006, 127:316.","journal-title":"Med Clin (Barc"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0789-5","article-title":"Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine","volume":"27","author":"Aslanidis S","year":"2008","unstructured":"Aslanidis S, Pyrpasopoulou A, Douma S, Triantafyllou A. Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine. Clin Rheumatol. 2008, 27:377-80. 10.1007\/s10067-007-0789-5","journal-title":"Clin Rheumatol"},{"key":"ref38","article-title":"New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?","volume":"34","author":"Roux CH","year":"2007","unstructured":"Roux CH, Brocq O, Leccia N, et al.. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?. J Rheumatol. 2007, 34:434-7.","journal-title":"J Rheumatol"},{"key":"ref39","article-title":"Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients","volume":"80","author":"Severs GA","year":"2007","unstructured":"Severs GA, Lawlor TH, Purcell SM, Adler DJ, Thompson R. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Cutis. 2007, 80:231-7.","journal-title":"Cutis"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.270","article-title":"Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases","volume":"143","author":"Ubriani R","year":"2007","unstructured":"Ubriani R, Van Voorhees AS. Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases. Arch Dermatol. 2007, 143:270-2. 10.1001\/archderm.143.2.270","journal-title":"Arch Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina U","year":"2008","unstructured":"Wollina U, Hansel G, Koch A, Sch\u00f6nlebe J, K\u00f6stler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008, 9:1-14. 10.2165\/00128071-200809010-00001","journal-title":"Am J Clin Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1177\/039463200902200331","article-title":"Psoriasis induced by infliximab in a patient suffering from Crohn's disease","volume":"22","author":"Manni E","year":"2009","unstructured":"Manni E, Barachini P. Psoriasis induced by infliximab in a patient suffering from Crohn's disease. Int J Immunopathol Pharmacol. 2009, 22:841-4. 10.1177\/039463200902200331","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.03127.x","article-title":"Psoriasiform eruption associated with alopecia areata during infliximab therapy","volume":"34","author":"Nakagomi D","year":"2009","unstructured":"Nakagomi D, Harada K, Yagasaki A, Kawamura T, Shibagaki N, Shimada S. Psoriasiform eruption associated with alopecia areata during infliximab therapy. Clin Exp Dermatol. 2009, 34:923-4. 10.1111\/j.1365-2230.2008.03127.x","journal-title":"Clin Exp Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1177\/039463200902200126","article-title":"Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis","volume":"22","author":"Bruzzese V","year":"2009","unstructured":"Bruzzese V, Pepe J. Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis. Int J Immunopathol Pharmacol. 2009, 22:235-8. 10.1177\/039463200902200126","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1177\/247553031016a00110","article-title":"Psoriasiform eruption following the treatment of cutaneous sarcoidosis with infliximab","volume":"16a","author":"Andrews ID","year":"2010","unstructured":"Andrews ID, Schlauder SM, Gottlieb AB. Psoriasiform eruption following the treatment of cutaneous sarcoidosis with infliximab. Psoriasis Forum. 2010, 16a:64-6. 10.1177\/247553031016a00110","journal-title":"Psoriasis Forum"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.4078\/jkra.2010.17.2.200","article-title":"Exacerbation of psoriatic skin lesion followed by TNF-alpha antagonist treatment","volume":"17","author":"Oh JM","year":"2010","unstructured":"Oh JM, Koh EM, Kim H, et al.. Exacerbation of psoriatic skin lesion followed by TNF-alpha antagonist treatment. J Korean Rheum Assoc. 2010, 17:200-4. 10.4078\/jkra.2010.17.2.200","journal-title":"J Korean Rheum Assoc"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181d59511","article-title":"Anti-TNF-associated palmoplantar pustulosis","volume":"16","author":"Pyrpasopoulou A","year":"2010","unstructured":"Pyrpasopoulou A, Chatzimichailidou S, Simoulidou E, Aslanidis S. Anti-TNF-associated palmoplantar pustulosis. J Clin Rheumatol. 2010, 16:138-9. 10.1097\/RHU.0b013e3181d59511","journal-title":"J Clin Rheumatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3109\/09546630902882089","article-title":"Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?","volume":"21","author":"Rallis E","year":"2010","unstructured":"Rallis E, Korfitis C, Stavropoulou E, Papaconstantis M. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?. J Dermatolog Treat. 2010, 21:3-5. 10.3109\/09546630902882089","journal-title":"J Dermatolog Treat"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3402\/ljm.v7i0.19139","article-title":"Beh\u00e7et's syndrome treated with infliximab, which caused a palmoplantar pustulosis, subsequently maintained on low-dose etanercept","volume":"7","author":"Tresh A","year":"2012","unstructured":"Tresh A, Smith VH, Parslew RA. Beh\u00e7et's syndrome treated with infliximab, which caused a palmoplantar pustulosis, subsequently maintained on low-dose etanercept. Libyan J Med. 2012, 7:10.3402\/ljm.v7i0.19139","journal-title":"Libyan J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22922","article-title":"Development of diffuse alopecia with psoriasis-like eruptions during administration of infliximab for Crohn's disease","volume":"19","author":"Kawashima K","year":"2013","unstructured":"Kawashima K, Ishihara S, Yamamoto A, Ohno Y, Fukuda K, Onishi K, Kinoshita Y. Development of diffuse alopecia with psoriasis-like eruptions during administration of infliximab for Crohn's disease. Inflamm Bowel Dis. 2013, 19:E33-4. 10.1002\/ibd.22922","journal-title":"Inflamm Bowel Dis"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e3182802c93","article-title":"Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy","volume":"19","author":"Broge T","year":"2013","unstructured":"Broge T, Nguyen N, Sacks A, Davis M. Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy. Inflamm Bowel Dis. 2013, 19:E75-7. 10.1097\/MIB.0b013e3182802c93","journal-title":"Inflamm Bowel Dis"},{"key":"ref52","article-title":"Infliximab: paradoxical psoriasis scalp eruption with alopecia: case report","volume":"1557","author":"Peinado C","year":"2015","unstructured":"Peinado C. Infliximab: paradoxical psoriasis scalp eruption with alopecia: case report. React Wkly. 2015, 1557:126-7.","journal-title":"React Wkly"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.14744\/bmj.2020.74755","article-title":"Successful treatment of paradoxical psoriasis with IL 17 inhibition","volume":"7","author":"G\u00fcle\u00e7 GG","year":"2020","unstructured":"G\u00fcle\u00e7 GG, Akta\u015f \u0130, \u00dcnl\u00fc \u00d6zkan F, Yurt N, Ar\u0131kan EE. Successful treatment of paradoxical psoriasis with IL 17 inhibition. Bosphorus Med J. 2020, 7:34-7. 10.14744\/bmj.2020.74755","journal-title":"Bosphorus Med J"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.7197\/cmj.842870","article-title":"Paradoxically Psoriasis, developed in a patient using adalimumab for ankylosing spondylitis: Case report","volume":"43","author":"\u0130rkin S","year":"2021","unstructured":"\u0130rkin S, \u00c7elik N\u00c7, Karaka\u015f B, Karata\u015f B, \u015eahin A. Paradoxically Psoriasis, developed in a patient using adalimumab for ankylosing spondylitis: Case report. Cumhur Medical J. 2021, 43:177-81. 10.7197\/cmj.842870","journal-title":"Cumhur Medical J"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1159\/000524174","article-title":"Clinical and epidemiological characteristics of hidradenitis suppurativa patients with paradoxical psoriasiform reactions following treatment with adalimumab","volume":"8","author":"Kanelleas A","year":"2022","unstructured":"Kanelleas A, Efthymiou O, Routsi E, et al.. Clinical and epidemiological characteristics of hidradenitis suppurativa patients with paradoxical psoriasiform reactions following treatment with adalimumab. Skin Appendage Disord. 2022, 8:415-8. 10.1159\/000524174","journal-title":"Skin Appendage Disord"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.5152\/tjr.2010.09","article-title":"Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: case series and literature overview","volume":"25","author":"Sarpel T","year":"2010","unstructured":"Sarpel T, Ba\u015faran S, Ak\u00e7am FD, G\u00fcna\u015ft\u0131 S, Denli Y. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: case series and literature overview. Arch Rheumatol. 2010, 25:091-4. 10.5152\/tjr.2010.09","journal-title":"Arch Rheumatol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1177\/2475530318810851","article-title":"TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management","volume":"4","author":"Li SJ","year":"2018","unstructured":"Li SJ, Perez-Chada LM, Merola JF. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis. 2018, 4:70-80. 10.1177\/2475530318810851","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071485","article-title":"Pathogenesis of paradoxical reactions associated with targeted biologic agents for inflammatory skin diseases","volume":"10","author":"Miyagawa F","year":"2022","unstructured":"Miyagawa F. Pathogenesis of paradoxical reactions associated with targeted biologic agents for inflammatory skin diseases. Biomedicines. 2022, 10:1485. 10.3390\/biomedicines10071485","journal-title":"Biomedicines"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study","volume":"42","author":"Pugliese D","year":"2015","unstructured":"Pugliese D, Guidi L, Ferraro PM, et al.. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015, 42:880-8. 10.1111\/apt.13352","journal-title":"Aliment Pharmacol Ther"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases","volume":"20","author":"Ko JM","year":"2009","unstructured":"Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009, 20:100-8. 10.1080\/09546630802441234","journal-title":"J Dermatolog Treat"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.3780040415","article-title":"Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference","volume":"4","author":"Kornbluth A","year":"1998","unstructured":"Kornbluth A. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis. 1998, 4:328-9. 10.1002\/ibd.3780040415","journal-title":"Inflamm Bowel Dis"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200721020-00007","article-title":"Adalimumab: in Crohn's disease","volume":"21","author":"Plosker GL","year":"2007","unstructured":"Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn's disease. BioDrugs. 2007, 21:125-32; discussion 133-4. 10.2165\/00063030-200721020-00007","journal-title":"BioDrugs"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002349","article-title":"Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease","volume":"69","author":"Courbette O","year":"2019","unstructured":"Courbette O, Aupiais C, Viala J, et al.. Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2019, 69:189-93. 10.1097\/MPG.0000000000002349","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/171150-paradoxical-tumor-necrosis-factor-alpha-tnf--inhibitor-induced-psoriasis-a-systematic-review-of-pathogenesis-clinical-presentation-and-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:37Z","timestamp":1707509017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/171150-paradoxical-tumor-necrosis-factor-alpha-tnf--inhibitor-induced-psoriasis-a-systematic-review-of-pathogenesis-clinical-presentation-and-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":63,"URL":"https:\/\/doi.org\/10.7759\/cureus.42791","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}